Kalaris Therapeutics Inc

KLRS

NASDAQ

Healthcare

Biotechnology

Cambridge, MA, US14 employeeskalaristx.com

$5.78

-0.15(-2.61%)

Mkt Cap $108M

$2.27

$10.98

52-Week Range

At a Glance

AI-generated

8-K

Kalaris Therapeutics, Inc. made available an updated corporate presentation on March 9, 2026, for use at The Leerink Partners Global Healthcare Conference and other conferences. The presentation provides updates on timelines for reporting data from the Phase 1b/2 multi-ascending dose clinical trial of TH103 and initiating Phase 3 clinical development, along with other clinical operations updates and cash runway guidance into Q4 2027.

$108M

Market Cap

—

Revenue

-$35M

Net Income

Employees14

Fundamentals

How The Business Makes Money

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Industry Biotechnology

Activity

What Changed Recently

Regulation FD

Mar 8, 2026

. Regulation FD Disclosure. On March 9, 2026, Kalaris Therapeutics, Inc. (the “Company”) made available an updated corporate presentation that it plans to use f

Peer Companies

Company	Price	Change	Market Cap	P/E
OVIDOvid Therapeutics Inc.	$2.19	+1.62%	$332M	-12.0
STTKShattuck Labs, Inc.	$6.43	+2.96%	$308M	-13.0
CNTXContext Therapeutics Inc.	$2.73	+3.02%	$251M	-10.9
STROSutro Biopharma, Inc.	$23.67	-4.83%	$201M	-0.8
CNTBConnect Biopharma Holding...	$3.00	+10.48%	$168M	-4.5
ARTVArtiva Biotherapeutics, I...	$6.76	+0.15%	$167M	-1.6
IFRXInflaRx N.V.	$0.92	+1.72%	$66M	-1.3
IMAImageneBio Inc	$5.07	+0.40%	$57M	-1.5

Analyst View

Company Profile

CIK0001754068

ISINUS4829291065

CUSIP482929106

Address139 Main Street, Suite 500, Cambridge, MA, 02142, US

SEC EDGAR